In a controversial move, a US biotechnology company has been given permission to recruit 20 clinically dead patients and try to bring their central nervous system back to life.
If they can successfully reanimate parts of the upper spinal cord, where the lower brain stem is located, there’s a possibility that they could kick start vital body functions such as breathing and heartbeats - something these patients can only do with the help of machines.
"This represents the first trial of its kind and another step towards the eventual reversal of death in our lifetime," CEO ofBioquark Inc., Ira Pastor, told Sarah Knapton at The Telegraph.
The Bioquark team, which together with Indian biotech company Revita Life Sciences, was granted permission from an institutional review board at the Indian and U.S. National Institutes of Health to begin clinical trials whenever they’re ready. Biquark says it plans to start recruiting patients for its so-called ReAnima Project immediately.
No comments:
Post a Comment